Source comparison
What Is CJC-1295 No DAC Peptide?: Research vs DAC-Modified Comparison
Half-Life ~30 minutes 6–8 days No DAC suits pulsatile GH studies; DAC suits sustained-release models No DAC preserves physiological GH rhythm. Critical for receptor sensitivity research Peak GH Response 20–30 min post-injection Sustained baseline elevation No
This comparison does not assign a generated winner or score.
- Half-Life
- ~30 minutes
- 6–8 days
- No DAC suits pulsatile GH studies; DAC suits sustained-release models
- No DAC preserves physiological GH rhythm. Critical for receptor sensitivity research
- Peak GH Response
- 20–30 min post-injection
- Sustained baseline elevation
- No DAC mimics endogenous ultradian pulses; DAC creates pharmacological steady-state
- Pulsatility vs continuity is the mechanistic difference. Not potency
- Albumin Binding
- None
- Covalent bond via maleimide-lysine
- No DAC clears renally; DAC persists in circulation bound to albumin
- Biodistribution differs. DAC-bound peptides have restricted tissue access
- Dosing Frequency
- Multiple administrations per protocol window
- Single administration lasts days
- No DAC requires timing precision; DAC simplifies dosing but alters pharmacodynamics
- Protocol complexity increases with no DAC but experimental control improves
- Receptor Occupancy Pattern
- Brief, pulsatile
- Sustained, continuous
- No DAC allows receptor recovery between pulses; DAC risks desensitization
- Chronic receptor stimulation with DAC may confound long-term metabolic studies